Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases — Stella

Home/Hypoxic-Ischemic Encephalopathy/Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases

View on ClinicalTrials.gov

Recruiting

Back to Hypoxic-Ischemic Encephalopathy trials

Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Qilu Children's Hospital of Shandong University, Jinan, Shandong

Key details

Sponsor

Shandong Qilu Stem Cells Engineering Co., Ltd.

Collaborators

Qilu Children's Hospital of Shandong University

Enrollment target

~120 participants

Started

April 2022

Primary completion

May 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

1 Day – 28 Days

Last updated May 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.